| |
All
|
KDIGO 0
|
KDIGO 1 or 2
| |
|---|
| |
Median
|
IQR
|
Median
|
IQR
|
Median
|
IQR
| P-valueb
|
|---|
Baseline | 0.3 | 0.13 to 0.59 | 0.33 | 0.13 to 0.73 | 0.27 | 0.12 to 0.525 | 0.6 |
End of surgery | 0.08 | 0.03 to 0.28 | 0.07 | 0.03 to 0.23 | 0.07 | 0.05 to 0.48 | 0.17 |
4 hr after CPB | 0.17 | 0.09 to 0.31 | 0.16 | 0.09 to 0.3 | 0.18 | 0.085 to 0.37 | 0.91 |
1 day postoperatively | 0.28 | 0.11 to 0.95 | 0.28 | 0.08 to 0.52 | 0.79 | 0.15 to 6.56 | 0.03 |
- aCPB, Cardiopulmonary bypass; IQR, Interquartile range. The median concentrations of urinary tissue inhibitor of metalloproteinase 2 (TIMP-2) combined with urine insulin-like growth factor binding protein 7 (IGFBP-7) ([TIMP-2] × [IGFBP-7]) (ng/ml)2/1,000 at four measurement time points sorted by Kidney Disease: Improving Global Outcomes (KDIGO) groups are displayed. [TIMP-2] × [IGFBP-7] concentration first decreased from baseline after surgery and then increased 4 hours after the arrest of CPB and increased further on the first postoperative day. On the day of surgery (measurement points 1, 2 and 3), no significant difference was found between patients with acute kidney injury (AKI) (KDIGO 1 or 2) and those without AKI (KDIGO 0). On the first postoperative day, patients with AKI had significantly higher concentrations of urinary [TIMP-2] × [IGFBP-7]. bP < 0.05 by Mann–Whitney U test was considered statistically significant.
